

DAFTAR PUSTAKA

1. Mauss S, Thomas RB, Jurgen S, Christoph W, Heiner, editors. Hepatology - A Clinical Textbook. 10 ed. Design : Hanno Schaaf; 2020. p. 155-57.
2. Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of hepatitis B surface antigen predict hepatitis b surface antigen seroclearance in patients with inactive chronic hepatitis b virus infection. *Clinical Gastroenterology Hepatology*. 2012;10:297-302.
3. WHO (2018). Hepatitis B. World Health Organization Western Pasific Region. www.who.int/news-room/fact-sheets/detail/hepatitis-B. Diakses Juli 2020.
4. Sanityoso A, Christine G. Hepatitis viral akut. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. 6 ed. Jakarta: Interna Publishing; 2014. p. 1952-1954.
5. Lavanchy D. Worldwide epidemiology of VHB infection, disease burden, and vaccine prevention. *Journal of Clinical Virology*. 2015; 5: 34.
6. Infodatin (2014). Situasi dan analisis hepatitis. Kementerian Kesehatan RI. www.pusdatin.kemkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-hepatitis.pdf. Diakses juli 2020.
7. PPHI. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia 2017. www.scribd.com/document/428606370/Konsensus-Nasional-Penatalaksanaan-Hepatitis-b. Diakses Juli 2020.
8. Litbangkes. Riset Kesehatan Dasar 2013. Kementerian Kesehatan Republik Indonesia. www.kemendes.go.id. Diakses Juli 2020.
9. Sandra F, Ayuningtiyas P, Iskandar M, editors. *Harrison Gastroenterologi dan Hepatologi*. Jakarta: EGC; 2013.p.351-355.
10. Yi P, Chen R, Huang Y, Zhou R, Fan X. Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges. *Journal of Hepatology*.2016; 8: 32–39.
11. Soemohardjo S, Gunawan S. Hepatitis B kronis. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. 6 ed. Jakarta: Interna Publishing; 2014. p. 1965-1977.

12. Kementerian Kesehatan Republik Indonesia. Peraturan Kemenkes RI no. 53 tahun 2015 tentang penanggulangan hepatitis virus. https://infeksiemerging.kemkes.go.id/download/PERMENKES_53_2015_Pena nggulangan_Hepatitis_Virus.pdf. Diakses Juli 2020.
13. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. *Hepatology*. 2010; 51: 415-421.
14. Liaw YF, J-H, Piratvisuth T, Chan HLY. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. *Hepatology International*. 2012; 6: 531-561.
15. Dewi DP, Sholikhah EN, Prairohardjon W. Respon terapi Analog Nukleosida (Lamivudin dan Telbivudin) dan Nukleotida (Tenofovir) pada pasien hepatitis B kronis di Instalasi Rawat Inap RSUP Dr. Sardjito Yogyakarta tahun 2014. Tesis Mahasiswa Fakultas Kedokteran UGM. 2016;1:1.
16. Li X, Jin Q, Xu H, Zhang Z, Zhou H, Niu J, et al. Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment. *Journal of Experimental Medicine*. 2017; 13: 3624-3630.
17. Calvaruso V, Craxi A. regression of fibrosis after HBV antiviral therapy is cirrhosis reversible. *Liver International*. 2014; 23: 85-90.
18. Sanityoso A, Christine G. Hepatitis viral akut. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata KM, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. 6 ed. Jakarta: Interna Publishing; 2014. p. 1953.
19. World Health Organization. Hepatitis B. Department of Communicable Diseases Surveillance and Response 2012. <https://www.hepb.org/treatment-and-management/drug-watch/>. Diakses Juli 2020.
20. Jalaluddin S. Transmisi virus hepatitis B. *Fakultas Ilmu Kedokteran dan Kesehatan Universitas Islam Negeri Alauddin Makassar*. 2018;8:48-52.
21. Ahn J, Salem SB, Cohen SM. Evaluation and Management of Hepatitis B in Pregnancy: A survey of Current Practices. *Gastroenterology & Hepatology Journal*. 2010; 6: 570-577.
22. Abbas, AK., Lichtman, AH., dan Pillai, S. Innate Immunity, in *Cellular and Molecular Immunology*. *The Lancet*. 2012;7:96-105.

23. Urban S, Schulze A, Dandri M, Petersen J. The Replication Cycle of Hepatitis B Virus. *Journal of Hepatology*. 2010; 52: 3-8.
24. Ait-goughoulte M, Lucifora J, Zoulim F, Durantel D. Innate Antivirus Immune Responses to Hepatitis B Virus. *Gastroenterology & Hepatology Journal*. 2012;43: 7-10.
25. Ishikawa, T. Immunoregulation of Hepatitis B Virus Infection, Rationale and Clinical Application. *Nagoya Journal of Medical science*. 2012; 34:13-15.
26. Neumann A, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, et al. Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells. *Gastroenterology & Hepatology Journal*. 2010; 64: 3-6.
27. Trhanpati N, Hissar S, Shrivastav S, Sarin SK. Immunological mechanisms of Hepatitis B Virus persistence. *Indian Journal Medical Research*. 2013; 16: 9-13.
28. Swalsh R, Locarnini S. Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise. *Yonsei Medical Journal*. 2012;22:5-7.
29. Yi P, Chen R, Huang Y, Zhou R, Fan X. Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges. *Journal of Hepatology*. 2016; 8: 316-318.
30. Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. *BMC Infectious Diseases*. 2011; 11: 165.
31. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, dan Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. *Hepatology*. 2010; 52: 1251-1257.
32. Fasano M, Lampertico P, Marzano A, Di Marco V, Brancaccio G. DNA VHB suppression and HBeAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. *Journal of Hepatology*. 2012; 56: 1254-1258.
33. Wang L, Chen E, Zhu X, Xiong Z, Liu L, Xu I, et al. Factors predicting the efficacy of adefovir dipivoxil on treatment-naive chronic hepatitis B patient at 48 weeks. *Gut and Liver*. 2011; 5: 478-485.

34. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology*. 2010 Feb; 51: 422-30.
35. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. *Gastroenterology*. 2011 Jan;1: 132-143.
36. Tarigan E, Yusuf RE, Dairy LB, Sembiring J, Sihombing MHM, Siregar GA, et al. Aspartate aminotransferase to platelet ratio index dan fibroscan for predicting liver fibrosis with chronic hepatitis B. Department Of Internal Medicine Faculty Of Medicine University Of Sumatera Utara. 2013;1:140.
37. Liu F, Wang WX, Chen L, Hu P, Ren H, Hu HD. Systematic review with metaanalysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. *Aliment Pharmacol Ther*. 2016; 43 (12): 1253-1261.
38. Ghani MG, Doo EC. Antiviral resistance and hepatitis B therapy. *Hepatology*. 2009; 49: 3-5.
39. Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, et al. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. *World Journal of Hepatology*. 2016;8:1402-1413.
40. Trinaningtyas RW, Sari CP, Setyaningrum N. Evaluasi terapi pada pasien hepatitis B di RSUP Dr.Sardjito Yogyakarta. *Jurnal Ilmiah Farmasi*. 2017;1: 29-34.
41. Broquetas T, Retortillo MG, Mico M, Canillas L, Puighehi M, Canete N, et al. Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. *World Journal of Hepatology*. 2020;11:1076-1088.
42. Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, et al. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. *Annals of Gastroenterology*. 2021;34:73-79.
43. Tang C., Yau T. O., dan Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. *World Journal of Gastroenterology*. 2014;20:6262-6278.

44. Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology*. 2018;4:1560-1599.
45. Buti M, Roade L, Barciela MR, Esteban R. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. *Liver International*. 2020; 40: 15-21.
46. Marcellin P, Wong DK, Sievert W, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. *Liver International*. 2019;10:1868-1875.
47. Agarwal K, Fung S, Seto WK, Lim Y, Gane E, Janssen H, Sharma M, et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B: efficacy and safety results at week 96. *Journal of Hepatology*. 2017; 66:478-488.
48. Tenggara IR, Lesmana CRA, Gani RA. Treatment Response Monitoring of Chronic Hepatitis B Patients using Transient Elastography and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI). *Journal Internal Medicine*. 2017; 49: 220-226.
49. Kim SU, Park JY, Kim do Y, Ahn SH, Choi EH, Seok JY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic Hepatitis B: impact of antiviral treatment on fibrosis regression. *Hepatol Int*. 2010;4: 673-680.
50. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. *World Journal Gastroenterology*. 2018;14:6154-6162.
51. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. *Gut and Liver*. 2017;56: 968- 973.
52. Wallace K, Burt AD, Wirth MC. Liver fibrosis. *Biochemical Journal*. 2018;411:1-8.
53. Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. *J Gastroenterol*. 2011;46:1324-1334.

54. Alice T, Cerutti F, Pittaluga F, Varetto S, Gabella S, Marzano A, Franchello A, et al. COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. *Journal Clin Microbiology*. 2017; 45:828–834.

